Puma Biotechnology Presents Results from Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer at the ASCO 2019 Annual Meeting

33

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology presented Phase III results of its NALA trial of neratinib in patients with HER2+ metastatic breast cancer at ASCO 2019. http://www.businesswire.com/news/home/20190604005616/en/Puma-Biotechnology-Presents-Results-Phase-III-NALA/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==